You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 165 No. 9, May 9, 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Thyroid/ Parathyroid Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Uncertain Natural History of Thyrotoxic Patients Treated With Combination Interferon Alfa-2{beta} and Ribavirin

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

While reading with interest the recent publication regarding thyroid dysfunction and hepatitis C in men,1 I noted a number of conundrums. First, there was no biochemical confirmation of thyroid function tests (TFTs) in the exclusion criteria other than simply excluding "patients with known thyroid disease." Second and similarly, there were no baseline TFTs in the recruited subjects. Third, the TFT testing protocol was an additional problem. Such frequency testing in this setting depends very much on the natural history, which can vary from weeks to months and is far from being completely understood.2-3 Therefore, currently there is no definitive recommendation regarding TFTs during the treatment course.4 Without such information, the concern is the probable misclassification of destructive autoimmune (bi-phasic) type "hyperthyroidism" into the "hypothyroidism" category. This point is best highlighted by the following clinical vignette.

A 40-year-old man with chronic hepatitis C (genotype 1) was treated with combination interferon alfa-2{beta} . . . [Full Text of this Article]


AUTHOR INFORMATION
Huy A. Tran, MD, FACE, FRCPA



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The natural history of interferon-{alpha}2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection
Tran et al.
QJM 2009;102:117-122.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.